AT
ATQP.F Vericel Corporation
- Market cap
- EUR 2.70B
- P/E
- 89.8x
- P/B
- 7.68x
- ROE
- 3.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ATQP.F undervalued?
Graham numberThe Graham number of Vericel Corporation cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Vericel Corporation fundamental analysis
No fundamental analysis for Vericel Corporation yet.
Vericel Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects o…
Full company profileVericel Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Vericel Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 54.4M | 63.9M | 90.9M | 118M | 124M | 156M | 164M | 198M | 237M | 276M | 308M |
| Gross Profit | 26.1M | 33.6M | 58.7M | 80.3M | 84.2M | 106M | 110M | 136M | 172M | 206M | 224M |
| Operating Income | -16.6M | -15.0M | -3.91M | -11.3M | 2.37M | -7.85M | -17.1M | -6.46M | 4.52M | 11.0M | 6.07M |
| EBITDA | - | -14.6M | -4.98M | -7.91M | 5.43M | -4.61M | -15.6M | 2.86M | 16.6M | 29.6M | 28.1M |
| Net Income | -19.6M | -17.3M | -8.14M | -9.67M | 2.86M | -7.47M | -16.7M | -3.18M | 10.4M | 16.5M | 13.4M |
| EPS | - | -0.48 | -0.19 | -0.22 | 0.06 | -0.16 | -0.35 | -0.07 | 0.21 | 0.33 | 0.26 |
| Balance Sheet | |||||||||||
| Total Assets | 48.6M | 54.6M | 119M | 153M | 206M | 244M | 273M | 354M | 433M | 488M | 517M |
| Total Liabilities | 23.9M | 32.0M | 16.5M | 42.1M | 71.3M | 73.2M | 80.7M | 128M | 141M | 133M | 133M |
| Shareholders' Equity | 24.7M | 22.5M | 102M | 111M | 134M | 170M | 192M | 226M | 292M | 355M | 384M |
| Cash & Short-term Investments | 23.0M | 26.9M | 18.3M | 26.9M | 33.6M | 68.3M | 51.1M | 69.1M | 74.5M | 100M | 133M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -19.9M | -13.2M | -412K | -7.18M | 17.6M | 29.0M | 17.7M | 35.3M | 58.2M | 51.9M | 67.1M |
| Capital Expenditure | 1.42M | 1.51M | 2.68M | 2.62M | 2.63M | 7.92M | 7.60M | 27.5M | 64.0M | 27.2M | 6.97M |
| Free Cash Flow | - | -14.7M | -3.09M | -9.80M | 14.9M | 21.1M | 10.1M | 7.80M | -5.81M | 24.7M | 60.1M |
| Ratios | |||||||||||
| ROE | -79.2% | -76.7% | -8.0% | -8.7% | 2.1% | -4.4% | -8.7% | -1.4% | 3.5% | 4.7% | 3.5% |
| ROA | -40.3% | -31.7% | -6.9% | -6.3% | 1.4% | -3.1% | -6.1% | -0.9% | 2.4% | 3.4% | 2.6% |
| Net Profit Margin | -36.0% | -27.0% | -9.0% | -8.2% | 2.3% | -4.8% | -10.2% | -1.6% | 4.4% | 6.0% | 4.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Vericel Corporation dividends
Vericel Corporation has not paid dividends in the last 9 fiscal years.
Last stock split: 1:20 on Oct 16, 2013.
Who owns Vericel Corporation
- Insiders 1.19%
- Institutions 98.81%
- Public & others 0.00%
- Shares outstanding 51.0M
- Free float 50.4M
Vericel Corporation company profile
- Company name
- Vericel Corporation
- Ticker
- ATQP.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 398
- Fiscal year end
- December
- Address
- 25 Blue Sky Drive, Burlington, MA, United States, 01803
- Phone
- 617 588 5555
- Website
- vcel.com
About Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.
Vericel Corporation management
10- Mr. Dominick C. Colangelo Esq.CEO, President & Director · born 1964
- Mr. Joseph Anthony Mara Jr.CFO & Treasurer · born 1976
- Mr. Michael HalpinChief Operating Officer · born 1962
- Mr. Sean C. FlynnChief Legal Officer · born 1974
- Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B.Chief Medical Officer · born 1962
- Mr. Jonathan D. SiegalPrincipal Accounting Officer, VP & Corporate Controller
- Mr. Eric BurnsVice President of Finance & Investor Relations
- Mr. Roland DeAngelisChief Marketing Officer
- Mr. Patrick J. FowlerSenior Vice President of Corporate Development & Strategy
- Mr. Mike GilliganSenior Vice President of Sales